RGNX News
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
Zacks
AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +27.27% and +299.42%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
REGENXBIO to Participate in Stifel 2026 Healthcare Conference REGENXBIO to Participate in Stifel 2026 Healthcare ConferencePR NewswireROCKVILLE, Md., Nov. 3, 2026 ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026...
PR Newswire
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsPR NewswireROCKVILLE, Md., Oct. 29, 2026 ROCKVILLE...
PR Newswire
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PR NewswireROCKVILLE, Md., Oct. 12, 2026Event to include clinical program overview and...
PR Newswire
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPR...
PR Newswire